FDA says Amarin can market fish-oil derived therapy for reducing heart attack risk

FDA says Amarin can market fish-oil derived therapy for reducing heart attack risk
Reuters: Health
U.S. health regulators on Friday approved expanding the heart benefit claims Amarin Corp can make in promoting its drug Vascepa to include reducing the risk of heart attacks and strokes in high-risk patients, opening a multibillion-dollar market opportunity.